Cyclosporin Mediator for Chemotherapy Ocular Side Effects

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Patients undergoing chemotherapy, antiviral, or immunomodulator treatments often experience ocular conditions such as nasolacrimal stenosis, keratoconjunctivitis, and conjunctivitis due to the side effects of these therapies, for which there is a need for effective prevention and treatment.

Innovation Solution

Administering cyclosporin, its analogs, or derivatives, either alone or in combination with therapeutically active agents like chemotherapy drugs or antiviral agents, to prevent or treat these ocular conditions, which can be done through various administration methods including systemic, local, or topical application, and may be concurrent or sequential with the primary treatment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If chemotherapy agents or antiviral agents are administered to treat cancer or viral infections, then therapeutic efficacy is improved, but ocular conditions such as nasolacrimal stenosis, keratoconjunctivitis, and conjunctivitis occur as side effects

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidocular conditions

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Cyclosporin A is introduced as an intermediary substance that mediates between the chemotherapy/antiviral treatment and the ocular tissues. It protects the ocular surface by modulating immune responses and reducing inflammation caused by the therapeutic agents, thereby preventing ocular conditions while allowing the primary treatment to maintain its efficacy

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

Cyclosporin A is administered preliminarily or concurrently with chemotherapy/antiviral agents to prevent the development of ocular side effects before they occur. This preliminary protective action counteracts the harmful effects of the primary treatment on ocular tissues without interfering with the therapeutic mechanism of the chemotherapy or antiviral agents

Inventive Principle:

Principle #9Preliminary anti-action

2Ease of operation

If current treatments are used for ocular conditions associated with chemotherapy, then treatment is provided, but the treatments fail to adequately address the underlying causes and provide sufficient relief

Engineering Contradiction:

Improvetreatment availabilityVSAvoidtreatment effectiveness

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The invention changes the therapeutic parameter by introducing cyclosporin A, which has different mechanisms of action compared to conventional ocular treatments. Cyclosporin A modifies immune responses and reduces inflammation at the molecular level, addressing the underlying causes of chemotherapy-induced ocular conditions rather than merely treating symptoms, thereby significantly improving treatment effectiveness

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20180325996A1Prevention and treatment of ocular side effects with a cyclosporin

Publication Date: 2018.11.15 ALLERGAN INC

AI summary

Therapeutic methods are disclosed herein.